{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:57:04Z","timestamp":1787803024212,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX006479"],"award-info":[{"award-number":["BX006479"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bone.2026.117933","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:54:03Z","timestamp":1778770443000},"page":"117933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease"],"prefix":"10.1016","volume":"210","author":[{"given":"Matthew R.","family":"Allen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne E.","family":"Metzger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Tinsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"DiMarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalisha","family":"O'Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Matter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2026.117933_bb0005","article-title":"Obesity and severe obesity prevalence in adults: United States, August 2021\u2013August 2023","author":"Emmerich","year":"2024","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.bone.2026.117933_bb0010","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.2215\/CJN.09500916","article-title":"Fractures in patients with CKD: time for action","volume":"11","author":"Moe","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bone.2026.117933_bb0015","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1681\/ASN.2009121208","article-title":"Bone mass and microarchitecture in CKD patients with fracture","volume":"21","author":"Nickolas","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bone.2026.117933_bb0020","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/ki.2008.264","article-title":"Chronic kidney disease and bone fracture: a growing concern","volume":"74","author":"Nickolas","year":"2008","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2026.117933_bb0025","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1681\/ASN.2005111194","article-title":"Relationship between moderate to severe kidney disease and hip fracture in the United States","volume":"17","author":"Nickolas","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bone.2026.117933_bb0030","article-title":"Chronic kidney disease: its relationship with obesity","volume":"14","author":"Prasad","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.bone.2026.117933_bb0035","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1001\/archinte.166.22.2502","article-title":"Bone mineral density response to caloric restriction\u2013induced weight loss or exercise-induced weight loss: a randomized controlled trial","volume":"166","author":"Villareal","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.bone.2026.117933_bb0040","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1210\/jc.2014-4341","article-title":"Two-year changes in bone density after Roux-en-Y gastric bypass surgery","volume":"100","author":"Yu","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.117933_bb0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bone.2026.117933_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.936651","article-title":"Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: an infodemiological study","volume":"9","author":"Dzaye","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.bone.2026.117933_bb0055","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/dom.14443","article-title":"Potential kidney protection with liraglutide and semaglutide: exploratory mediation analysis","volume":"23","author":"Mann","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bone.2026.117933_bb0060","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2026.117933_bb0065","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s00198-025-07664-1","article-title":"Effects of glucagon-like peptide-1 receptor agonists on bone health in people living with obesity","volume":"36","author":"Karam","year":"2025","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.117933_bb0070","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1210\/en.2007-1292","article-title":"The murine glucagon-like peptide-1 receptor is essential for control of bone resorption","volume":"149","author":"Yamada","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.bone.2026.117933_bb0075","first-page":"1","article-title":"The crucial role of beta-catenin in the osteoprotective effect of semaglutide in an ovariectomized rat model of osteoporosis","author":"Abo-Elenin","year":"2024","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.bone.2026.117933_bb0080","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bone.2015.08.006","article-title":"Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice","volume":"81","author":"Pereira","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.117933_bb0085","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.3390\/ph17121655","article-title":"Effects of semaglutide and tirzepatide on bone metabolism in type 2 diabetic mice","volume":"17","author":"Lv","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bone.2026.117933_bb0090","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3390\/medicina58020224","article-title":"The impact of GLP1 agonists on bone metabolism: a systematic review","volume":"58","author":"Daniilopoulou","year":"2022","journal-title":"Medicina"},{"key":"10.1016\/j.bone.2026.117933_bb0095","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/jbmr.2089","article-title":"A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD","volume":"29","author":"Moe","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117933_bb0100","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1002\/jbmr.485","article-title":"The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat","volume":"26","author":"Moe","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117933_bb0105","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/ki.2008.456","article-title":"A rat model of chronic kidney disease-mineral bone disorder","volume":"75","author":"Moe","year":"2009","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2026.117933_bb0110","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00198-012-2103-x","article-title":"Skeletal effects of zoledronic acid in an animal model of chronic kidney disease","volume":"24","author":"Allen","year":"2013","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.117933_bb0115","doi-asserted-by":"crossref","first-page":"7936","DOI":"10.1038\/s41598-019-44415-9","article-title":"Effect of ovariectomy on the progression of chronic kidney disease-mineral bone disorder (CKD-MBD) in female Cy\/+ rats","volume":"9","author":"Vorland","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bone.2026.117933_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170225","article-title":"Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates","volume":"125","author":"Knerr","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.bone.2026.117933_bb0125","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.cmet.2023.07.010","article-title":"GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss\u2014chemistry, physiology, and clinical applications","volume":"35","author":"Campbell","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.bone.2026.117933_bb0130","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad074","article-title":"Chronic semaglutide treatment in rats leads to daily excessive concentration-dependent sucrose intake","volume":"7","author":"Cawthon","year":"2023","journal-title":"J. Endocr. Soc."},{"key":"10.1016\/j.bone.2026.117933_bb0135","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bone.2026.117933_bb0140","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10837","article-title":"The dietary fiber inulin slows progression of chronic kidney disease\u2013mineral bone disorder (CKD-MBD) in a rat model of CKD","volume":"7","author":"Biruete","year":"2023","journal-title":"JBMR Plus"},{"key":"10.1016\/j.bone.2026.117933_bb0145","article-title":"Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease","volume":"16","author":"Swallow","year":"2022","journal-title":"Bone Rep."},{"key":"10.1016\/j.bone.2026.117933_bb0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00223-026-01479-w","article-title":"A high fat\/high sucrose diet alters the skeletal response to adenine-induced chronic kidney disease in male rats","volume":"117","author":"Metzger","year":"2026","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2026.117933_bb0155","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/jbmr.1805","article-title":"Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee","volume":"28","author":"Dempster","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117933_bb0160","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/8756-3282(93)90081-K","article-title":"Basic biomechanical measurements of bone: a tutorial","author":"Turner","year":"1993","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.117933_bb0165","series-title":"Proc. SIGCHI Conf. Hum. Factors Comput. Syst","first-page":"143","article-title":"The aligned rank transform for nonparametric factorial analyses using only anova procedures","author":"Wobbrock","year":"2011"},{"key":"10.1016\/j.bone.2026.117933_bb0170","series-title":"34th Annu. ACM Symp. User Interface Softw. Technol","first-page":"754","article-title":"An aligned rank transform procedure for multifactor contrast tests","author":"Elkin","year":"2021"},{"key":"10.1016\/j.bone.2026.117933_bb0175","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.bone.2011.07.017","article-title":"Issues in modern bone histomorphometry","volume":"49","author":"Recker","year":"2011","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.117933_bb0180","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1681\/ASN.2007050555","article-title":"The effect of raloxifene treatment in postmenopausal women with CKD","volume":"19","author":"Cummings","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bone.2026.117933_bb0185","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1916","article-title":"Rapid cortical bone loss in patients with chronic kidney disease","volume":"28","author":"Nickolas","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2026.117933_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0099262","article-title":"Cortical bone mechanical properties are altered in an animal model of progressive chronic kidney disease","volume":"9","author":"Newman","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2026.117933_bb0195","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.2215\/CJN.0000000000000254","article-title":"Changes in bone quality after treatment with etelcalcetide","volume":"18","author":"Khairallah","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.bone.2026.117933_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/bcp.70566","article-title":"The interplay of GLP-1 receptor agonist use, chronic kidney disease and fracture risk in obese pAtients: a retrospective cohort study","author":"Eubanks","year":"2026","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bone.2026.117933_bb0205","series-title":"Calcitonin and Raloxifene Each Improve Mechanical Properties of Diseased Bone Through Non-Cell Mediated Mechanisms","author":"Surowiec","year":"2023"},{"key":"10.1016\/j.bone.2026.117933_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2025.117415","article-title":"Combined Romosozumab and Raloxifene treatment targets impaired bone quality in a male murine model of diabetic kidney disease","author":"Kohler","year":"2025","journal-title":"Bone"},{"key":"10.1016\/j.bone.2026.117933_bb0215","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/ki.2015.315","article-title":"Raloxifene improves skeletal properties in an animal model of cystic chronic kidney disease","volume":"89","author":"Newman","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.bone.2026.117933_bb0220","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00198-014-2978-9","article-title":"Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic kidney disease","volume":"26","author":"Allen","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.117933_bb0225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00223-015-9997-1","article-title":"Bone material properties and skeletal fragility","volume":"97","author":"Fyhrie","year":"2015","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2026.117933_bb0230","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3390\/ph18071058","article-title":"Weight loss effects of once-weekly semaglutide 2.4 mg in adults with and without type 2 diabetes: a systematic review and meta-analysis","volume":"18","author":"Hong","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bone.2026.117933_bb0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0250438","article-title":"Adenine-induced chronic kidney disease induces a similar skeletal phenotype in male and female C57BL\/6 mice with more severe deficits in cortical bone properties of male mice","volume":"16","author":"Metzger","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.bone.2026.117933_bb0240","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae004","article-title":"Inhibition of RANKL improves the skeletal phenotype of adenine-induced chronic kidney disease in mice","volume":"8","author":"Metzger","year":"2024","journal-title":"JBMR Plus"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226001596?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226001596?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:28:39Z","timestamp":1784647719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226001596"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":48,"alternative-id":["S8756328226001596"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.117933","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.117933","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117933"}}